Lab Manager | Run Your Lab Like a Business

Cytiva Launches Xcellerex Automated Perfusion System for More Efficient Manufacture of Biotherapeutics

New system simplifies processes and reduces risk when intensifying upstream operations


Cytiva is a 3.3 billion USD global life sciences leader with nearly 7,000 employees across 40 sites dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that...

ViewFull Profile.
Learn about ourEditorial Policies.
Register for free to listen to this article
Listen with Speechify
Cytiva's Xcellerex Automated Perfusion System.

Cytiva, a global life sciences leader, is introducing an innovation to the market that supports the biotech industry’s move to continuous manufacturing. Called the Xcellerex Automated Perfusion System (APS), it simplifies processes and reduces risk when intensifying upstream operations.

In cell cultivation using perfusion, media is continuously fed and product harvested. This increases output compared to traditional batch or fed batch methods, yet perfusion processes still involve substantial manual work and risk. Overcoming this challenge by simplifying and automating upstream operations would alleviate bottlenecks further along the perfusion process, increasing overall productivity and output.

Get training in Lab Crisis Preparation and earn CEUs.One of over 25 IACET-accredited courses in the Academy.
Lab Crisis Preparation Course

Olivier Loeillot, senior vice president, BioProcess, says: “Simplifying upstream bioprocess workflows is one way we deliver on Cytiva’s mission to advance and accelerate therapeutics. Along with our end-to-end flexible manufacturing solutions, automation technology and trusted expertise, we have introduced Xcellerex APS to support the industry’s journey to integrated continuous manufacturing.”

Xcellerex APS system integrates with Cytiva’s Xcellerex XDR bioreactors for continuous upstream bioprocessing operations. The system’s automation capabilities include automated filter switching, liquid management and cell bleed, which reduces risk for human error and increases process robustness.

The continuous manufacturing market for biologics is estimated to be valued at USD 310 million in 2030 representing a CAGR of 23 percent (2020 – 2030)1. Over 50 percent of more than 200 companies polled in 2020 by independent market analyst, BioPlan, were found to be planning to actively or informally evaluate continuous upstream technologies in the next 12 months2.

See how Xcellerex APS works.


  1. Roots Analysis Research and Consulting Group (2020) Continuous Manufacturing Market Research Report (Small Molecules and Biologics), 2020 – 2030, page 37.
  2. Langer, E.S, (April 2020) A Study of Biotherapeutic Developers and Contract Manufacturing Organizations BioPlan 17th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, page 465.
Cytiva Logo

Cytiva UK Limited

Amersham Place
Little Chalfont
Buckinghamshire England HP7 9NA